Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
China Patent Challenge Compels Gilead to Withdraw Key Patent Claims on Sofosbuvir Base Compound, Opening Life-Saving Hepatitis C Treatment Access for Millions
Reality check on PBMs and drug costs
Patent abuse driving high drug prices, non-profit claims
Brainstorm Health: BeiGene IPO, Amerisource CEO on Amazon, California Data Privacy Law
Axios Vitals: Patents = profits (Article 3)
Report: Hundreds of Patents on America’s Top Selling Drugs are Triggering Price Hikes and Blocking Competition
AbbVie faces hepatitis C patent challenge in India
Brief: AbbVie Hepatitis C Treatment Patents Challenged In India For Evergreening
Conceptualizing Minimum Core Beyond Affordable Goods And Services – Trade For Human Rights As A Minimum Core Obligation
I-MAK & Patients for Affordable Drugs File Amicus Brief with the US Supreme Court in support of RPX Corp in RPX Corp. v. Chanbond LLC